trending Market Intelligence /marketintelligence/en/news-insights/trending/2qixecajujhpujkxudwa8g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Allergan exec responsible for leading Botox franchise joins Evolus

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Allergan exec responsible for leading Botox franchise joins Evolus

Irvine, Calif.-based Evolus Inc. said it appointed Michael Jafar as chief marketing officer.

Jafar, the former vice president of medical aesthetics at Allergan PLC, will join Evolus, which is looking to market a copycat version of Botox.

Botox is Allergan's blockbuster drug, which is used to fill wrinkles and treat migraine headaches.

Jafar led product development and market initiatives for the Botox Cosmetic, Juvederm, Kybella, Latisse and Natrelle franchises at Allergan.

"I am confident that Mike will have an immediate impact on our organization and bring a fresh perspective to our team as we further develop and execute our commercial strategy," Evolus President and CEO David Moatazedi said in a statement.

In May, the U.S. Food and Drug Administration rejected Evolus' application to market DWP-450 for wrinkles.

DWP-450, also known as prabotulinumtoxinA, is expected to compete with Botox. Evolus said it would work with the regulator to address the issues raised and expects to launch the treatment by spring 2019.